Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Assets Average (2020 - 2026)

ADC Therapeutics has reported Assets Average over the past 7 years, most recently at $307.3 million for Q1 2026.

  • Quarterly results put Assets Average at $307.3 million for Q1 2026, up 3.39% from a year ago — trailing twelve months through Mar 2026 was $307.3 million (up 3.39% YoY), and the annual figure for FY2025 was $322.6 million, down 4.67%.
  • Assets Average reached $307.3 million in Q1 2026 per ADCT's latest filing, roughly flat from $306.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $551.2 million in Q2 2022 and bottomed at $297.0 million in Q2 2025.
  • Median Assets Average over the past 5 years was $360.4 million (2024), compared with a mean of $398.1 million.
  • The largest annual shift saw Assets Average rose 19.65% in 2022 before it crashed 30.28% in 2024.
  • Over 5 years, Assets Average stood at $459.9 million in 2022, then dropped by 10.67% to $410.8 million in 2023, then fell by 18.33% to $335.5 million in 2024, then dropped by 8.67% to $306.5 million in 2025, then increased by 0.28% to $307.3 million in 2026.
  • Business Quant data shows Assets Average for ADCT at $307.3 million in Q1 2026, $306.5 million in Q4 2025, and $305.7 million in Q3 2025.